Illumina, Inc. $ILMN Stock: Fulcrum Asset Management LLP Raises Position

Fulcrum Asset Management LLP boosted its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 3,405.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 31,447 shares of the life sciences company’s stock after buying an additional 30,550 shares during the period. Fulcrum Asset Management LLP’s holdings in Illumina were worth $8,554,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Signature Equity Partners LLC raised its holdings in shares of Illumina by 246.5% in the 3rd quarter. Signature Equity Partners LLC now owns 149 shares of the life sciences company’s stock valued at $41,000 after acquiring an additional 106 shares in the last quarter. Fiduciary Financial Advisors bought a new stake in shares of Illumina during the 2nd quarter valued at about $26,000. MCF Advisors LLC boosted its position in shares of Illumina by 172.4% during the 2nd quarter. MCF Advisors LLC now owns 158 shares of the life sciences company’s stock valued at $28,000 after acquiring an additional 100 shares during the last quarter. Keating Financial Advisory Services Inc. bought a new stake in shares of Illumina during the 2nd quarter valued at about $32,000. Finally, Rakuten Securities Inc. purchased a new position in shares of Illumina during the second quarter worth about $33,000. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Keith Meister sold 50,000 shares of the stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $227.17, for a total transaction of $11,358,500.00. Following the completion of the sale, the director owned 488,917 shares of the company’s stock, valued at approximately $111,067,274.89. This represents a 9.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 1,601,541 shares of company stock valued at $354,755,291 in the last ninety days. Insiders own 2.90% of the company’s stock.

Illumina Price Performance

ILMN opened at $213.13 on Monday. The company has a market cap of $32.23 billion, a P/E ratio of 36.68, a P/E/G ratio of 2.89 and a beta of 1.46. The business’s 50-day moving average price is $249.15 and its 200-day moving average price is $178.12. The company has a current ratio of 2.63, a quick ratio of 2.05 and a debt-to-equity ratio of 0.57. Illumina, Inc. has a 12 month low of $112.65 and a 12 month high of $309.35.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, October 29th. The life sciences company reported $1.62 earnings per share for the quarter, beating the consensus estimate of $1.36 by $0.26. Illumina had a return on equity of 28.38% and a net margin of 19.72%. The company had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.15 billion. During the same period in the prior year, the business posted $1.34 EPS. Illumina’s quarterly revenue was up 4.2% compared to the same quarter last year. On average, equities analysts expect that Illumina, Inc. will post 5.43 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ILMN. Evercore restated an “underperform” rating on shares of Illumina in a research report on Friday, October 30th. Deutsche Bank Aktiengesellschaft lowered shares of Illumina to a “hold” rating in a research report on Wednesday, August 5th. Stephens cut shares of Illumina from an “overweight” rating to an “equal weight” rating and set a $275.00 price target for the company. in a research note on Friday, October 23rd. Zacks Research lowered shares of Illumina from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 1st. Finally, Sanford C. Bernstein reissued a “market perform” rating and issued a $215.00 price target on shares of Illumina in a report on Friday, July 31st. Ten investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $244.24.

Illumina Profile

Illumina, Inc develops and supplies technologies used to analyze genetic variation and biological function. Its products include next-generation sequencing systems, microarrays, reagents and consumables, as well as software and related services that help customers generate and interpret genomic data.

The company’s technology is used in applications such as medical and population research, genetic testing, drug development, and agricultural and environmental studies. Its customers include academic and government research institutions, hospitals and clinical laboratories, biotechnology and pharmaceutical companies, and other organizations around the world.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers internationally.